As a continuation of our research on developing anticancer agents and based on the proven proprieties of thieno[2,3‐b]pyridines as anticancer, we have designed to synthesize novel thieno[2,3‐b]pyridine derivatives that incorporate different biologically active heterocycles through various chemical reactions. All of the newly obtained compounds, compared with the standard anticancer drug (doxorubicin)
作为我们开发抗癌药的继续研究,并基于
噻吩并[2,3- b ]
吡啶作为抗癌药的可靠特性,我们设计了合成新型
噻吩并[2,3- b ]
吡啶衍生物的方法,该衍
生物结合了不同的
生物活性通过各种
化学反应形成杂环。与标准抗癌药(
阿霉素)相比,所有新获得的化合物均在体外筛选了其对肝细胞癌(HepG-2)和人乳腺癌(MCF-7)
细胞系的抗肿瘤活性。结果表明,化合物3,7,12,和19被认为是最有效的对抗表现出IC既肝癌HepG-2和MCF-7
细胞系50个值分别在3.67至11.50和5.13至11.80μg/ mL之间,其中化合物7对参比药物
阿霉素对HepG-2
细胞系的活性更高,显示IC 50值为3.67μg/ mL(
阿霉素4.65微克/毫升)。